News
LNTH
79.94
-2.46%
-2.02
Analysts Forecast 15% Gains Ahead For IJK
NASDAQ · 2d ago
Press Release: Lantheus to Host Fourth Quarter and Full Year 2024 Earnings Conference Call and Webcast on February 26, 2025, at 8:00 a.m. Eastern Time
Dow Jones · 3d ago
Weekly Report: what happened at LNTH last week (0203-0207)?
Weekly Report · 5d ago
Weekly Report: what happened at LNTH last week (0127-0131)?
Weekly Report · 02/03 10:14
Lantheus Appoints Dr. Morrow to Board of Directors
TipRanks · 01/30 13:58
LANTHEUS APPOINTS PHUONG KHANH (P.K.) MORROW, M.D., AS NEW BOARD MEMBER
Reuters · 01/30 13:30
Press Release: Lantheus Appoints Phuong Khanh (P.K.) Morrow, M.D., as New Board Member
Dow Jones · 01/30 13:30
Lantheus’s Strategic Acquisition of Evergreen Theragnostics Strengthens Radiopharmaceutical Leadership and Growth Prospects
TipRanks · 01/30 08:36
Strategic Acquisitions and Market Growth Propel Lantheus to a Buy Rating
TipRanks · 01/29 14:05
BUZZ-Lantheus falls on up to $1 billion acquisition
Reuters · 01/28 18:17
Strategic Expansions and Acquisitions Position Lantheus for Growth in Oncology and Radiopharma Sectors
TipRanks · 01/28 18:15
Lantheus Holdings’ Strategic Advancements and Acquisitions Reinforce Buy Rating
TipRanks · 01/28 17:45
LNTH Makes Notable Cross Below Critical Moving Average
NASDAQ · 01/28 16:39
Lantheus To Buy Evergreen Theragnostics For Over $1 Billion To Bolster Its Cancer Radiopharmaceutical Portfolio
Benzinga · 01/28 15:32
Lantheus backs FY24 adjusted EPS view $6.65-$6.70, consensus $6.75
TipRanks · 01/28 12:02
Lantheus to acquire Evergreen Theragnostics for $250M upfront
TipRanks · 01/28 11:55
Lantheus to Acquire Evergreen Theragnostics for $250 Million
TipRanks · 01/28 11:48
LANTHEUS HOLDINGS INC - REAFFIRMS FULL-YEAR AND Q4 2024 FINANCIAL GUIDANCE
Reuters · 01/28 11:30
Lantheus to acquire Evergreen Theragnostics
Seeking Alpha · 01/28 11:13
Lantheus To Acquire Evergreen Theragnostics; Reaffirms Guidance
NASDAQ · 01/28 11:13
More
Webull provides a variety of real-time LNTH stock news. You can receive the latest news about Lantheus Holding through multiple platforms. This information may help you make smarter investment decisions.
About LNTH
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company engaged in delivering science to enable clinicians to find, fight and follow diseases to deliver patient outcomes. It classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Radiopharmaceutical Oncology diagnostics and therapeutics help healthcare professionals (HCPs) find, fight and follow cancer, with a focus on prostate cancer. Precision Diagnostic products assist HCPs to find and follow diseases, with a focus in cardiology. Strategic Partnerships focus on enabling precision medicine through the use of biomarker solutions, digital solutions, and radiotherapeutic platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, and others. Its pipeline includes B amyloid positron emission tomography (PET) imaging agent, NAV-4694, also known as F18-flutafuranol. It has pre-clinical assets, specifically the TROP2 and DUNP19.